Financial Performance - The company reported a revenue of HKD 22,334 thousand for the six months ended September 30, 2024, a decrease of 9.0% compared to HKD 24,555 thousand in the same period last year[8]. - The pre-tax loss for the period was HKD 2,038 thousand, slightly improved from a loss of HKD 2,145 thousand in the previous year, indicating a reduction in losses[8]. - The basic loss per share was HKD 0.51, compared to HKD 0.54 in the same period last year, reflecting a 5.6% improvement in per-share performance[11]. - The company has reported a total comprehensive loss of HKD 2,048 thousand for the period, compared to HKD 2,123 thousand in the previous year, showing a slight improvement[10]. - The company recorded a pre-tax loss of HKD 12,188,000 for the six months ended September 30, 2024, compared to a pre-tax loss of HKD 12,511,000 in the same period of 2023, showing a slight improvement of about 2.6%[29]. - The loss attributable to the company's owners for the six months ended September 30, 2024, was HKD 2.0 million, a decrease of HKD 0.1 million or 4.2% from HKD 2.1 million in the same period of 2023[50]. - The company recorded a loss attributable to owners of HKD 2.0 million for the six months ending September 30, 2024, a decrease of HKD 0.1 million or 4.2% from a loss of HKD 2.1 million in the previous year[62]. Revenue Breakdown - Revenue from medical consultation services decreased to HKD 535,000 from HKD 589,000, a decline of approximately 9.2% year-over-year[22]. - Revenue from prescription and dispensing services fell to HKD 4,112,000 from HKD 4,749,000, representing a decrease of about 13.4%[22]. - Revenue from treatment services decreased to HKD 17,687,000 from HKD 19,217,000, a decline of approximately 7.9%[22]. - The revenue breakdown includes medical consultation services at HKD 0.5 million (2.4%), prescription and dispensing services at HKD 4.1 million (18.4%), and treatment services at HKD 17.7 million (79.2%) of total revenue[50]. Assets and Liabilities - Total assets as of September 30, 2024, amounted to HKD 45,972 thousand, an increase from HKD 40,060 thousand as of March 31, 2024[13]. - The company's net asset value decreased to HKD 5,533 thousand from HKD 7,581 thousand as of March 31, 2024, representing a decline of 27.0%[13]. - Inventory levels increased to HKD 4,799 thousand from HKD 4,315 thousand, indicating a rise of 11.2% in stock held[13]. - The company has a total current liability of HKD 37,461 thousand, up from HKD 31,740 thousand, reflecting a 17.5% increase in obligations[13]. - Non-current liabilities include long service payment obligations of HKD 799 thousand, which increased from HKD 739 thousand[13]. - The company's current liabilities net value was HKD 3.1 million, primarily arising from contract liabilities of HKD 20.3 million, which are expected to be fulfilled without cash outflow[19]. - The total equity as of September 30, 2024, was HKD 5.5 million, down from HKD 7.6 million as of March 31, 2024[65]. - The debt-to-equity ratio as of September 30, 2024, was 162.7%, indicating a significant increase in leverage compared to the previous period[65]. Cash Flow - The company reported a net cash inflow from operating activities of HKD 982,000 for the six months ended September 30, 2024, compared to HKD 2,831,000 in the same period of 2023, indicating a decrease of approximately 65.3%[16]. - The company’s cash and cash equivalents increased to HKD 12,938,000 as of September 30, 2024, compared to HKD 3,351,000 at the end of the same period in 2023, indicating a significant increase of approximately 286.5%[16]. - The company’s financing activities generated a net cash inflow of HKD 5,134,000 for the six months ended September 30, 2024, compared to a net cash outflow of HKD 3,850,000 in the same period of 2023[16]. Operational Efficiency - The company continues to focus on enhancing its operational efficiency and exploring new market opportunities to drive future growth[8]. - The group has implemented cost-saving measures and enhanced operational efficiency to improve performance amid challenges in the market[48]. Staffing and Governance - The company employed 29 full-time and 14 part-time employees as of September 30, 2024, maintaining the same staffing levels as of March 31, 2024[76]. - The board of directors is led by Dr. Jiang, who serves as both the chairman and CEO, ensuring alignment with the company's business strategy[86]. - The audit committee has been established in accordance with GEM listing rules and consists of three independent non-executive directors[96]. - The audit committee reviewed the unaudited interim financial statements for the six months ending September 30, 2024, and confirmed compliance with applicable accounting standards and GEM listing rules[96]. - The interim financial statements have been adequately disclosed as per regulatory requirements[96]. Shareholder Information - As of September 30, 2024, Dr. Jiang holds a controlling interest in 274,865,400 shares, representing 69.28% of the issued share capital of the company[78]. - Topline Worldwide Limited, wholly owned by Dr. Jiang, is the registered holder of the 274,865,400 shares, which are considered beneficially owned by Dr. Jiang[81]. - No other directors or key executives hold any interests or short positions in the company's shares or related securities as of September 30, 2024[80]. Dividends and Share Options - The board did not recommend an interim dividend for the six months ended September 30, 2024, consistent with the previous year[32]. - The old share option scheme, adopted on December 3, 2014, will expire on December 3, 2024, with no unexercised options remaining as of March 31, 2024[91]. - A new share option scheme was adopted on September 27, 2024, to attract and retain talent, with a total of 39,673,600 options available under the new plan[93]. - No share options were granted, exercised, vested, lapsed, or cancelled during the six months ending September 30, 2024[94]. Other Information - There were no significant events occurring after the reporting period[44]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending September 30, 2024[89]. - The company has no significant investments or capital asset plans as of September 30, 2024[68][69]. - The company does not have any major contingent liabilities as of September 30, 2024[74]. - There are no known direct or indirect competitive businesses or interests held by directors or controlling shareholders as of September 30, 2024[84]. - The company has complied with the corporate governance code as of September 30, 2024, with no known deviations[85].
密迪斯肌(08307) - 2025 - 中期业绩